AMIC teams with GSG International for Mo-99, Tech-99 distribution deal

Editorial Staff | | Health Imaging | Molecular Imaging

Advanced Medical Isotope Corporation (AMIC) has entered into a strategic alliance with GSG International to collaborate in the joint development of technologies for the production of medical isotopes and the marketing and distribution of related isotopes, equipment and services.

The alliance will first work together on the worldwide distribution of Molybendum-99 and Technetium-99 generators and kits acquired or manufactured by GSG, according to a release issued by Kennewick, Wash.-based AMIC.

AMIC initially will have exclusive rights for sale and distribution in North America, South America and China, and may later obtain additional rights subject to the alliance’s performance.

Editorial Staff

Related Content

New radiopharmaceutical targeted at gastrointenstinal cancers yields impressive results
New PET method combines antibody with radioactive isotope to improve lung cancer detection
ALS drug repurposed for PET imaging
New radiotracer has 'incredible potential' to improve management of spinal cord injuries
Frontotemporal dementia often misdiagnosed due to misinterpretations of imaging
Endometriosis imaging agent impresses at clinical trials

Around the web

Cardiovascular Business
ASE updates recommendations for assessing right heart function in patients with pulmonary hypertension

The new guidelines were designed to ensure sonographers and other members of the heart team have the information they need to screen patients when appropriate and identify early warnings signs of PH. 

Radiology Business
Shift toward imaging outside the hospital could save billions

Harvard’s David A. Rosman, MD, MBA, explains how moving imaging outside of hospitals could save billions of dollars for U.S. healthcare.

Cardiovascular Business
‘A significant milestone’: First US patients receive doses of new PET radiotracer for CAD

Back in September, the FDA approved GE HealthCare’s new PET radiotracer, flurpiridaz F-18, for patients with known or suspected CAD. It is seen by many in the industry as a major step forward in patient care.